Measures for simulator evaluation of a helicopter obstacle avoidance system

The U.S. Army Aeroflightdynamics Directorate (AFDD) has developed a high-fidelity, full-mission simulation facility for the demonstration and evaluation of advanced helicopter mission equipment. The Crew Station Research and Development Facility (CSRDF) provides the capability to conduct one- or two-crew full-mission simulations in a state-of-the-art helicopter simulator. The CSRDF provides a realistic, full field-of-regard visual environment with simulation of state-of-the-art weapons, sensors, and flight control systems. We are using the CSRDF to evaluate the ability of an obstacle avoidance system (OASYS) to support low altitude flight in cluttered terrain using night vision goggles (NVG). The OASYS uses a laser radar to locate obstacles to safe flight in the aircraft's flight path. A major concern is the detection of wires, which can be difficult to see with NVG, but other obstacles--such as trees, poles or the ground--are also a concern. The OASYS symbology is presented to the pilot on a head-up display mounted on the NVG (NVG-HUD). The NVG-HUD presents head-stabilized symbology to the pilot while allowing him to view the image intensified, out-the-window scene through the HUD. Since interference with viewing through the display is a major concern, OASYS symbology must be designed to present usable obstacle clearance information with a minimum of clutter

Pion, kaon, proton and anti-proton transverse momentum distributions from p+p and d+Au collisions at sNN=200\sqrt{s_{NN}} = 200 GeV

Identified mid-rapidity particle spectra of $\pi^{\pm}$, $K^{\pm}$, and $p(\bar{p})$ from 200 GeV p+p and d+Au collisions are reported. A time-of-flight detector based on multi-gap resistive plate chamber technology is used for particle identification. The particle-species dependence of the Cronin effect is observed to be significantly smaller than that at lower energies. The ratio of the nuclear modification factor ($R_{dAu}$) between protons $(p+\bar{p})$ and charged hadrons ($h$) in the transverse momentum range $1.2<{p_{T}}<3.0$ GeV/c is measured to be $1.19\pm0.05$(stat)$\pm0.03$(syst) in minimum-bias collisions and shows little centrality dependence. The yield ratio of $(p+\bar{p})/h$ in minimum-bias d+Au collisions is found to be a factor of 2 lower than that in Au+Au collisions, indicating that the Cronin effect alone is not enough to account for the relative baryon enhancement observed in heavy ion collisions at RHIC.Comment: 6 pages, 4 figures, 1 table. We extended the pion spectra from transverse momentum 1.8 GeV/c to 3. GeV/

Transverse-momentum ptp_t correlations on (η,ϕ)(\eta,\phi) from mean-ptp_{t} fluctuations in Au-Au collisions at sNN=\sqrt{s_{NN}} = 200 GeV

We present first measurements of the pseudorapidity and azimuth $(\eta,\phi)$ bin-size dependence of event-wise mean transverse momentum $$ fluctuations for Au-Au collisions at $\sqrt{s_{NN}} = 200$ GeV. We invert that dependence to obtain $p_t$ autocorrelations on differences $(\eta_\Delta,\phi_\Delta)$ interpreted to represent velocity/temperature distributions on ($\eta,\phi$). The general form of the autocorrelations suggests that the basic correlation mechanism is parton fragmentation. The autocorrelations vary strongly with collision centrality, which suggests that fragmentation is strongly modified by a dissipative medium in the more central Au-Au collisions relative to peripheral or p-p collisions. \\Comment: 7 pages, 3 figure

A Multicenter, Randomized, Placebo‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis

Objective: Rheumatoid arthritis (RA) is associated with increased cardiovascular event (CVE) risk. The impact of statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention of CVEs in RA patients. Methods: A randomized, double‐blind, placebo‐controlled trial was designed to detect a 32% CVE risk reduction based on an estimated 1.6% per annum event rate with 80% power at P 50 years or with a disease duration of >10 years who did not have clinical atherosclerosis, diabetes, or myopathy received atorvastatin 40 mg daily or matching placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, transient ischemic attack, or any arterial revascularization. Secondary and tertiary end points included plasma lipids and safety. Results: A total of 3,002 patients (mean age 61 years; 74% female) were followed up for a median of 2.51 years (interquartile range [IQR] 1.90, 3.49 years) (7,827 patient‐years). The study was terminated early due to a lower than expected event rate (0.70% per annum). Of the 1,504 patients receiving atorvastatin, 24 (1.6%) experienced a primary end point, compared with 36 (2.4%) of the 1,498 receiving placebo (hazard ratio [HR] 0.66 [95% confidence interval (95% CI) 0.39, 1.11]; P = 0.115 and adjusted HR 0.60 [95% CI 0.32, 1.15]; P = 0.127). At trial end, patients receiving atorvastatin had a mean ± SD low‐density lipoprotein (LDL) cholesterol level 0.77 ± 0.04 mmoles/liter lower than those receiving placebo (P < 0.0001). C‐reactive protein level was also significantly lower in the atorvastatin group than the placebo group (median 2.59 mg/liter [IQR 0.94, 6.08] versus 3.60 mg/liter [IQR 1.47, 7.49]; P < 0.0001). CVE risk reduction per mmole/liter reduction in LDL cholesterol was 42% (95% CI −14%, 70%). The rates of adverse events in the atorvastatin group (n = 298 [19.8%]) and placebo group (n = 292 [19.5%]) were similar. Conclusion: Atorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol level than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists’ Collaboration meta‐analysis of statin effects in other populations

Isogeometric Analysis for Topology Optimization with a Phase Field Model

We consider a phase field model for the formulation and solution of topology optimization problems in the minimum compliance case. In this model, the optimal topology is obtained as the steady state of the phase transition described by the generalized Cahn-Hilliard equation which naturally embeds the volume constraint on the amount of material available for distribution in the design domain. We reformulate the model as a coupled system and we highlight the dependency of the optimal topologies on dimensionless parameters. We consider Isogeometric Analysis for the spatial approximation which facilitates encapsulating the exactness of the representation of the design domain in the topology optimization and is particularly suitable for the analysis of phase field problems. We demonstrate the validity of the approach and numerical approximation by solving two and three-dimensional topology optimization problems. © 2012 CIMNE, Barcelona, Spain

Isogeometric analysis of the advective Cahn-Hilliard equation: Spinodal decomposition under shear flow

We present a numerical study of the spinodal decomposition of a binary fluid undergoing shear flow using the advective Cahn-Hilliard equation, a stiff, nonlinear, parabolic equation characterized by the presence of fourth-order spatial derivatives. Our numerical solution procedure is based on isogeometric analysis, an approximation technique for which basis functions of high-order continuity are employed. These basis functions allow us to directly discretize the advective Cahn-Hilliard equation without resorting to a mixed formulation. We present steady state solutions for rectangular domains in two-dimensions and, for the first time, in three-dimensions. We also present steady state solutions for the two-dimensional Taylor-Couette cell. To enforce periodic boundary conditions in this curved domain, we derive and utilize a new periodic Bézier extraction operator. We present an extensive numerical study showing the effects of shear rate, surface tension, and the geometry of the domain on the phase evolution of the binary fluid. Theoretical and experimental results are compared with our simulations. © 2013 Elsevier Inc